Related Experiment Video
Updated: Jun 6, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Treatment of high-risk neuroblastoma with anti-GD2 antibodies
Victoria Castel1, Vanessa Segura, Adela Cañete
1Grupo de Neuroblastoma SEHOP, Unidad de Oncología Pediátrica, Hospital Universitario La Fe, Valencia, Spain. castel_vic@gva.es
Abstract:
Anticancer monoclonal antibodies (mAbs) targeting specific antigens on the tumour surface are increasingly being applied in cancer treatment. Potential advantages include long half-life, low toxicity, high affinity and specificity. In order to develop novel immune therapies for high-risk cancers, finding tumour targets that are not widely shared by normal cells is a goal. GD2-disialoganglioside is one of them. It is expressed on the surface of a variety of tumours with no curative therapies for patients with advanced disease. In childhood, neuroblastoma is the most common GD2-expressing tumour. Because of this tumour-selective expression, it is an attractive target for tumour-specific therapies such as antibody therapy. Over the last two decades, several anti-GD2 antibodies have been developed. To reduce both toxicity and development of human anti-mouse antibodies (HAMA), research efforts have primarily focused on exploring anti-GD2 antibodies that substitute mouse components by human ones. This review will examine antibodies currently undergoing clinical testing as well as the most recent advances to improve antibody therapy for patients with high-risk neuroblastoma.
Insights
Monoclonal antibodies targeting GD2 are promising for high-risk cancers like neuroblastoma. Research focuses on humanized anti-GD2 antibodies to improve efficacy and reduce toxicity in patients.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Biology
Background:
- Anticancer monoclonal antibodies (mAbs) offer targeted cancer treatment with potential for high specificity and low toxicity.
- GD2-disialoganglioside is a tumor-specific antigen found on high-risk cancers, notably neuroblastoma, making it an attractive therapeutic target.
- Current treatments for advanced GD2-expressing cancers lack curative options, highlighting the need for novel therapies.
Purpose of the Study:
- To review advancements in anti-GD2 antibody therapies for high-risk cancers, particularly neuroblastoma.
- To examine antibodies in clinical testing and strategies to enhance antibody therapy.
- To explore the potential of GD2 as a target for tumor-specific immune therapies.
Main Methods:
- Review of existing literature on anti-GD2 antibodies.
- Analysis of clinical trial data for anti-GD2 antibodies.
- Examination of strategies to improve antibody therapy, including humanization to reduce human anti-mouse antibody (HAMA) response.
Main Results:
- Several anti-GD2 antibodies have been developed over the past two decades.
- Focus on humanizing anti-GD2 antibodies to minimize toxicity and HAMA development.
- Ongoing clinical investigations of anti-GD2 antibodies for high-risk neuroblastoma.
Conclusions:
- Anti-GD2 antibodies represent a promising avenue for treating GD2-expressing tumors, especially neuroblastoma.
- Humanized anti-GD2 antibodies are crucial for improving therapeutic outcomes and patient safety.
- Continued research and clinical evaluation are essential to optimize antibody therapy for high-risk cancers.
